142410-Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy.pdf (2.16 MB)
Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy
journal contributionposted on 2023-05-20, 20:18 authored by Kourakis, S, Timpani, CA, de Haan, JB, Nuri GuvenNuri Guven, Fischer, D, Rybalka, E
Imbalances in redox homeostasis can result in oxidative stress, which is implicated in various pathological conditions including the fatal neuromuscular disease Duchenne Muscular Dystrophy (DMD). DMD is a complicated disease, with many druggable targets at the cellular and molecular level including calcium-mediated muscle degeneration; mitochondrial dysfunction; oxidative stress; inflammation; insufficient muscle regeneration and dysregulated protein and organelle maintenance. Previous investigative therapeutics tended to isolate and focus on just one of these targets and, consequently, therapeutic activity has been limited. Nuclear erythroid 2-related factor 2 (Nrf2) is a transcription factor that upregulates many cytoprotective gene products in response to oxidants and other toxic stressors. Unlike other strategies, targeted Nrf2 activation has the potential to simultaneously modulate separate pathological features of DMD to amplify therapeutic benefits. Here, we review the literature providing theoretical context for targeting Nrf2 as a disease modifying treatment against DMD.
Publication titleRedox Biology
Department/SchoolSchool of Pharmacy and Pharmacology
Place of publicationNetherlands
Rights statementCopyright 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license